Immunoadsorption therapy for myasthenia gravis.
Immunoadsorption therapy for myasthenia gravis.
复制标题
重症肌无力的免疫吸附疗法。
DOI：
--
复制
发表时间：
1994
影响因子：
11
通讯作者：
Sachiko Kawanami
中科院分区：
文献类型：
--
作者：
N. Shibuya;Takeshi Sato;M. Osame;T. Takegami;S. Doi;Sachiko Kawanami
对一项多中心试验的结果进行分析，以评估免疫吸附疗法对严重全身性重症肌无力的疗效。根据标准化治疗方案，20 名重症肌无力患者同时接受高剂量泼尼松龙和硫唑嘌呤治疗，并使用色氨酸连接的聚乙烯醇凝胶 (IM-TR) 进行亲和型吸附剂治疗。这20名患者在10天内接受了5次吸附治疗。 11日，肌无力明显改善，并维持长期缓解。该治疗对胸腺增生患者尤其有效。通过处理一体积血浆，循环乙酰胆碱受体 (AChR) 抗体减少约 60%。胸腺增生患者和胸腺瘤患者的AChR抗体去除率没有差异。 100 次手术中未出现严重并发症。结论是，IM-TR 免疫吸附疗法可有效控制原本无反应的严重重症肌无力患者的症状。
The results of a multicentre trial were analysed to evaluate the efficacy of immunoadsorption therapy for severe generalised myasthenia gravis. Twenty patients with myasthenia gravis who were concurrently receiving high dose prednisolone and azathioprine therapy were treated with an affinity-type adsorbent, using tryptophan-linked polyvinyl alcohol gel (IM-TR), according to a standardised treatment protocol. The 20 patients received five adsorption treatments within a period of 10 days. In 11, pronounced improvement of myasthenic weakness was seen and long-term remission was maintained. The treatment was especially effective in patients with thymic hyperplasia. Circulating acetylcholine receptor (AChR) antibodies were reduced by about 60% by treating one plasma volume. There was no difference in the rate of removal of the AChR antibodies between patients with thymic hyperplasia and patients with thymoma. No serious complications occurred during 100 procedures. It was concluded that the immunoadsorption therapy with IM-TR is useful in controlling symptoms in patients with severe myasthenia gravis who are otherwise unresponsive.
DOI：
10.1073/pnas.79.1.188
发表时间：
1982-01-01
期刊：
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES
影响因子：
--
作者：
TZARTOS, SJ;SEYBOLD, ME;LINDSTROM, JM
通讯作者：
LINDSTROM, JM